Abstract: Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Abstract: Provided are novel fully human monoclonal antibodies that bind to human LAG-3. It also provides the methods of hybridoma generation using humanized rats, the nucleic acid molecules encoding the anti-LAG-3 antibodies, expression vectors and host cells used for the expression of anti-LAG-3 antibodies. The invention further provides the methods for validating the function of antibodies in vitro. The antibodies of invention provide a potent agent for the treatment of multiple cancers via modulating human immune function.

Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.

Abstract: The present invention relates to bifunctional molecules comprising an IL-7 variant and having a particular scaffold and their uses.

Abstract: The present invention provides a bispecific antibody and use thereof, and the bispecific antibody or an antigen-binding fragment of the present invention can bind to two or more antigens or two or more epitopes of a same antigen. The antibody or the antigen-binding fragment of the present invention can be used to treat a variety of diseases, such as inflammatory diseases, autoimmune diseases, cancers or spinal cord injury, and can also be used for diagnosis and prognosis of related diseases.

Abstract: The invention relates generally to anti-PD-L1 antibodies, and recombinant sialidase and anti-PD-L1 immunoglobulin antigen-binding domain fusion proteins. The invention also provides antibody conjugates including a sialidase and an anti-PD-L1 antibody or a portion thereof. The invention further relates to methods of using the antibodies, sialidase fusion proteins, or antibody conjugates for treating cancer.

Abstract: The invention relates generally to feline antibody variants and uses thereof. Specifically, the invention relates to mutations in the constant region of feline antibody for improving its half-life and other characters.

Abstract: Provided herein are antibodies that specifically bind to MICA/B having variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions disclosed herein, as well as methods and uses thereof.

Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.

Abstract: Provided are compositions and methods for treating or ameliorating a cancer by targeting cell surface-expressed ?v?3 (avb3) polypeptides in Cancer Stem Cells (CSCs) to kill the CSCs, thus treating ameliorating or slowing the development of cancers caused or initiated by or sustained by cancer or tumor cells, or Cancer Stem Cells (CSCs), expressing ?v?3 polypeptides on their cell surfaces. Provided are compositions and methods for targeting and killing ?v?3-positive Cancer Stem Cells (CSCs) and treating drug resistant cancers. In alternative embodiments, compositions and methods as provided herein use an antibody that can specifically bind to human ?v?3 that also comprises an Fc portion that can mediate antibody-dependent un-mediated cytotoxicity (ADCC) killing of cancer or tumor cells by macrophages; for example, use a humanized antibody to ?v?3 that has been modified to include an engineered Fc portion that specifically binds to human macrophages.

Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.

Abstract: The present disclosure provides methods of treating liver cancer in a subject in need thereof by administering a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.

Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the glycosyl-phosphatidylinositol (GPI)-linked GDNF family protein ?-receptor 4 (GFR?4).

Abstract: Provided are various embodiments relating to anti-IL4R antibodies that bind to canine IL4R. In various embodiments, such anti-IL4R antibodies can be used in methods to treat IL4/IL13-induced conditions, such as atopic dermatitis, allergic dermatitis, pruritus, asthma, psoriasis, scleroderma and eczema, in companion animals, such as canines and felines. Also provided are various embodiments relating to variant IgG Fc polypeptides and variant light chain constant regions of companion animal species for the preparation of antibodies or bispecific antibodies.

Abstract: Provided herein are IL-15 cytokine prodrugs and methods of making and using thereof.

Abstract: The present disclosure provides antibodies and antibody fragments thereof that bind to human TNFR2. The disclosed antibodies, inhibit the TNF-TNFR2 signaling axis and enhance cytokine secretion in T effector cells and are therefore useful for the treatment of cancer, either alone or in combination with other agents.

Abstract: The application provides anti-4-1BB monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.

Abstract: Antibodies or antigen binding fragments thereof that bind HVEM, inhibit HVEM-BTLA interaction and allow binding to LIGHT are provided. Methods of treating disease with these antibodies or antigen binding fragments thereof, nucleic acid molecules encoding these antibodies or antigen binding fragments thereof and kits comprising these antibodies or antigen binding fragments thereof are also provided.

Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

Abstract: The invention provides an anti-C5 humanized monoclonal antibody with low immunogenicity and low ADCC/CDC function and its application. By modifying the amino acid sequence of the framework region of Eculizumab monoclonal antibody, the immunogenicity was reduced, and the antibody was replaced from IgG2 subtype to IgG1 subtype, and a flexible amino acid sequence was inserted between the CDR3 and CH2 regions of the heavy chain of the IgG1 antibody to reduce the immunogenicity. The purpose of ADCC/CDC function is to improve the stability of the antibody and prolong its half-life. The binding affinity of the monoclonal antibody of the invention to human C5 is similar to that of the original Eculizumab antibody, it can specifically block the complement hemolytic activity of C5 and the production of C5a and can be used for the preparation of C5-targeted paroxysmal nocturnal hemoglobinuria and atypical the drug for the treatment of hemolytic uremic syndrome has excellent clinical therapeutic value.

Abstract: Disclosed herein are humanized antibodies, antigen-binding fragments thereof, and antibody conjugates, that are capable of specifically binding to certain biantennary Lewis antigens, which antigens are expressed in a variety of cancers. The presently disclosed antibodies are useful to target antigen-expressing cells for treatment or detection of disease, including various cancers. Also provided are polynucleotides, vectors, and host cells for producing the disclosed antibodies and antigen-binding fragments thereof. Pharmaceutical compositions, methods of treatment and detection, and uses of the antibodies, antigen-binding fragments, antibody conjugates, and compositions are also provided.

Abstract: Provided is an isolated antigen-binding protein, which can specifically bind to CD73 and includes at least one CDR in a heavy chain variable region VH, wherein the region VH includes an amino acid sequence as represented by SEQ ID NO: 49.

Abstract: An isolated monoclonal antibody capable of specifically binding to Trop2 is provided, together with a nucleic acid molecule encoding the antibody, as well as an expression vector, a host cell, and a method for expressing the antibody. An immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus, and a pharmaceutical composition containing the antibody, and a diagnostic or therapeutic method using the antibody are also provided.

Abstract: The present invention generally relates to antibodies that bind to GPRC5D, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

Abstract: Provided are an antibody or antigen-binding portion thereof that binds to MASP-2, and a use of the antibody or antigen-binding portion thereof in the preparation of a drug or kit for diagnosing, treating or preventing diseases associated with lectin pathway of complement activation. The antibody can specifically recognize enzymatic activity domains CCP1-CCP2-SP of human, monkey, mouse and rat MASP-2, and effectively inhibit the production of a complement component C4b and a C3 convertase C4b2a.

Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Abstract: The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.

Abstract: Disclosed are materials and methods for improved single chain variable fragments.

Abstract: The present invention concerns the field of antibodies. More specifically, it relates to an antibody which specifically binds to a hapten being fentanyl or a derivative thereof, said antibody binding to the hapten with an equilibrium dissociation constant (Kd) of at most 1.000 pM, at most 800 pM, at most 600 pM, at most 400 pM, at most 200 pM, at most 100 pM or at most 75 pM, wherein the binding pocket for the hapten comprises amino acids from all three complementary determining regions (CDRs) of each chain. The present invention also relates to a polynucleotide encoding said antibody, a vector or expression construct comprising the polynucleotide, a host cell comprising the polynucleotide or the vector or expression construct or a non-human transgenic organism comprising said polynucleotide or said vector or expression construct.

Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.

Abstract: The present disclosure relates to compositions and methods of engineered IgG Fc constructs, wherein the Fc constructs include one or more Fc domains.

Abstract: The present invention relates to antibodies binding to IL13 and IL22. The invention provides novel multi-specific antibodies that bind to both IL13 and IL22 and compositions comprising an antibody that binds to IL13 and an antibody that binds to IL22. The invention further relates to therapeutic uses of the combination of anti-IL13 and anti-IL22 antibodies and multi-specific antibodies that bind to both IL13 and IL22.

Abstract: A mill dried colloidal microcrystalline cellulose (MCC) is obtained in a process comprising the steps of a) providing colloidal MCC having a moisture content of from 20 to 75 percent, based on the total weight of the moist colloidal MCC; and b) mill-drying the moist colloidal MCC in a single device capable of milling and drying in combination. The process can provide mill-dried colloidal microcrystalline cellulose having similar particle size distribution (LEFI, DIFI and EQPC), and a similar or higher tapped/untapped bulk density, a similar or lower Carr index, a similar or higher viscosity and a similar moisture content as the corresponding spray-dried colloidal microcrystalline cellulose.

Abstract: The present disclosure relates to compositions comprising mixtures of hydroxypropyl-?-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-?-cyclodextrins.

Abstract: An invert emulsion having double particle size distribution, the invert emulsion having a particle size distribution of latex particles between 20 nm and 70 nm and between 100 nm and 500 nm in the same invert emulsion system. A preparation method for an invert emulsion comprises: forming an emulsion A and an emulsion B having different particle sizes by controlling an emulsifier system and an emulsification means, and preparing in one step an invert emulsion the particle size of which has bimodal distribution by means of a three-stage polymerization reaction between the emulsion A and the emulsion B in the same system. The invert emulsion is used as a water treatment flocculant, a sludge dewatering agent and a papermaking auxiliary agent, and in particular, the sludge dewatering agent fabricated from the invert emulsion is used for dewatering sludge.

Abstract: A photo-curable composition can include a photo-curable resin and a photoinitiator. The photo-curable composition can typically include a (meth)acrylate-terminated prepolymer, a second prepolymer, and a reactive diluent.

Abstract: The solid titanium catalyst component (I) of the present invention contains titanium, magnesium, halogen, and a cyclic multiple-ester-group-containing compound (a) represented by the following formula (1).

Abstract: A solid titanium catalyst component (I) for olefin polymer production contains titanium, magnesium, halogen, and a cyclic multiple-ester-group-containing compound (a) represented by the formula (1). Preferably, a propylene polymer that is obtained by the olefin polymerization method and has specific thermal properties as determined primarily by differential scanning calorimetry (DSC).

Abstract: A process for preparing a procatalyst for polymerization of olefins, comprising contacting a magnesium-containing support with a halogen-containing titanium compound, and an internal electron donor according to Formula (I), said process comprising the steps of: i) contacting a compound R4zMgX42-z with an alkoxy- or aryloxy-containing silane compound to give a first intermediate reaction product, being a solid Mg(OR1)xX12-x, ii) optionally contacting the solid Mg(OR1)xX12-x obtained in step ii) with at least one activating compound selected from the group formed by activating electron donors and metal alkoxide compounds of formula M1(OR2)v-w(OR3)w or M2(OR2)v-w(R3)w, to obtain a second intermediate product; iii) contacting the first or second intermediate reaction product, obtained respectively in step i) or ii), with a halogen-containing Ti-compound and said compound represented Formula (I), as the internal electron donor.

Abstract: A process for the recovery and recycling of unreacted monomer in a one-step process for the production of a carbon-fiber precursor. An integrated and improved single-step process for the production of a carbon-fiber precursor is also described, which starts from the co-monomers and reaches the spinning step obtaining the final precursor fiber, which provides for the recovery of the unreacted monomers at the end of the polymerization step and their recycling to the polymerization process itself.

Abstract: A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.

Abstract: A waterborne polyurethane acrylate emulsion, comprising the following raw material components: a polyurethane acrylate prepolymer and a polyurethane acrylate oligomer. After ultraviolet curing, the waterborne polyurethane acrylate emulsion exhibits excellent mechanical strength and good wear resistance. The matt coatings produced therefrom has a fine matt fineness after curing.

Abstract: Industrial hemp infused polyurethane spray foam insulation compositions are disclosed including a first component and a second component. The first component includes isocyanate, and the second component includes a mixture of polyol and industrial hemp. The first component and the second component are simultaneously mixed and sprayed using a spray gun to form the industrial hemp infused polyurethane spray foam insulations.

Abstract: A polythiol composition according to exemplary embodiments includes: a polythiol-based compound; and a benzyl halide-based reaction regulator in an amount of 10 ppm to 2,000 ppm based on a weight of the polythiol-based compound. The reaction rate of the polythiol-based compound and an isocyanate-based compound may be controlled through the reaction regulator to inhibit a generation of stria phenomenon.

Abstract: Disclosed herein is a process for producing polyurethanes including mixing (a) aromatic polyisocyanate with (b) polymeric compounds having isocyanate-reactive groups, (c) optionally chain extender and/or crosslinking agent, (d) catalyst, (e) 0.1% to 5% by weight, based on the total weight of the components (a) to (f), of at least one cyclic urea structure of general formula 1 where —X— represents a substituted or unsubstituted, 3-membered radical and R represents a radical (f) optionally blowing agent and (g) optionally additives to afford a reaction mixture and reacting the reaction mixture to afford the polyurethane. Further disclosed herein are a polyurethane obtainable by such a process and a method of using such a polyurethane foam for producing cushions, seat pads and mattresses.

Abstract: An epoxy compound having an aromatic ring represented by Formula 1 or Formula 2, a composition prepared from the epoxy compound, a semiconductor device prepared from the epoxy compound, an electronic device prepared from the epoxy compound, an article prepared from the epoxy compound, and a method of preparing the epoxy compound: E1-(M1)a1-(L1)b1-(M2)a2-L2-A1-L3-(M3)a3-(L4)b2-(M4)a4-E2??Formula 1 E3-(A2)c1-(L5)b3-(M5)a5-L6-(M6)a6-L7-(M7)a7-(L8)b4-(A3)c2-E4??Formula 2 In Formulae 1 and 2, M1, M2, M3, M4, M5, M6, M7, A1, A2, A3, L1, L2, L3, L4, L5, L6, L7, L8, E1, E2, E3, E4, a1, a2, a3, a4, a5, a6, a7, b1, b2, b3, b4, c1, and c2 are the same as defined in the detailed description.

Abstract: This invention relates to compositions of conducting polymers and their producing methods and applications in sensing technology. The present conducting polymer comprises an electron deficient and an electron rich building block in an alternated repeating unit which can function as sensors to detect, qualify or quantify analytes in fluid and exhibit chemiresistive property and stable performance in normal room temperature and air pressure. In one embodiment, the present invention provides compositions of conducting polymers and devices comprising the present compositions or conducting polymers for sensor application. In another embodiment, the present invention provides methods of detecting target molecules using compositions, conducting polymers or devices of the present invention. The target molecules include without limitation volatile organic compounds (VOCs) which are indicative of the presence or stage or a disease, or indicative of a health status of a subject.